# Clinical Trial Evaluating Gastrointestinal Damage Following Administration PL3100 or Naproxen in At-Risk Adults

> **NCT01139190** · PHASE2 · COMPLETED · sponsor: **PLx Pharma** · enrollment: 77 (actual)

## Conditions studied

- Gastroduodenal Ulcerations
- Erosion

## Interventions

- **DRUG:** PL3100
- **DRUG:** Naproxen

## Key facts

- **NCT ID:** NCT01139190
- **Lead sponsor:** PLx Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2016-04-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01139190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01139190, "Clinical Trial Evaluating Gastrointestinal Damage Following Administration PL3100 or Naproxen in At-Risk Adults". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01139190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*